Celularity Inc Cash Flow Conversion Efficiency
Celularity Inc cash flow conversion efficiency. Based on the latest financial reports, Celularity Inc (CELU) has a cash flow conversion efficiency ratio of 0.207x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.16 Million) by net assets ($-20.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Celularity Inc (2018–2024)
Cash flow conversion efficiency of Celularity Inc from 2018 to 2024. This chart illustrates how Celularity Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Celularity Inc stock quote for real-time trading data and today's change.
Celularity Inc Cash Flow Conversion Ratio Explained
Celularity Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Celularity Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celularity Inc ranked by their cash flow conversion efficiency. Also see market value of Celularity Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rubean AG
F:R1B
|
N/A |
|
Sikko Industries Limited
NSE:SIKKO
|
-0.100x |
|
Eqva ASA
OL:EQVA
|
0.112x |
|
CHINA NEW ENERGY LS-00025
F:9H5
|
N/A |
|
Demire Deutsche Mittelstand Real Estate AG
F:DMRE
|
-0.002x |
|
ecotel communication ag
XETRA:E4C
|
0.058x |
|
Wolftank Group AG
XETRA:WAH
|
0.165x |
|
Okong Corporation
KQ:045060
|
0.044x |
Annual Cash Flow Conversion Efficiency for Celularity Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Celularity Inc from 2018 to 2024. Review Celularity Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.84 Million | $-6.40 Million | -0.724x | +23.31% |
| 2023-12-31 | $40.96 Million | $-38.69 Million | -0.944x | -36.25% |
| 2022-12-31 | $198.90 Million | $-137.88 Million | -0.693x | +37.40% |
| 2021-12-31 | $99.42 Million | $-110.10 Million | -1.107x | +67.21% |
| 2020-12-31 | $18.71 Million | $-63.19 Million | -3.377x | -42306.64% |
| 2019-12-31 | $137.86 Million | $-1.10 Million | -0.008x | -284.56% |
| 2018-12-31 | $-125.85K | $-543.00 | 0.004x | -- |
About Celularity Inc
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioB… Read more